

**Date and Time:** Tuesday 12<sup>th</sup> November 2013  
10:00 – 16:30

**Minutes:** Confirmed

**Guideline Development Group Meeting Diabetes in pregnancy guideline update**

**Place:** Royal College of Obstetricians and Gynaecologists  
London

**Present:** Rudy Bilous (Chair) (RB) (Present for notes 1 – 9)  
Anne Dornhorst (AD) (Present for notes 1 – 9)  
Jacqueline Berry (JB) (Present for notes 1 – 9)  
Aderonke Kuti (AK) (Present for notes 1 – 9)  
Michael Maresh (MM) (Present for notes 1 – 9)  
Katharine Stanley (KS) (Present for notes 1 – 9)  
Elizabeth Stenhouse (ES) (Present for notes 1 – 9)  
Diane Todd (DT) (Present for notes 1 – 9)

**In attendance:**

NCC-WCH staff: David James (DJ) Shona Burman-Roy (SBR) Cristina Visintin (CV) Paul Jacklin (PJ) Sarah Bailey (SB)		(Present for notes 1 – 9) (Present for notes 1 – 5)
NICE attendees: Sarah Dunsdon		(Present for notes 1 – 9)

**Observers:**

None		
------	--	--

**Notes**

1. RB welcomed the group to the meeting. Apologies were received from Judy Shakespeare and Stacia Smales.
2. RB asked the group for any new declarations of interest.  
No new declarations of interest were received from the GDG members or the other attendees.  
(Declarations are kept on record at the NCC-WCH and will be published in the full guideline.)  
The minutes of the previous meeting were accepted as an accurate record of the meeting.
3. RB gave a feedback to the GDG from Diabetes Oversight Group meeting on the 24 October 2013.
4. CV presented the reviews on ketone monitoring in the preconception period and during pregnancy (Evidence Summary and Recommendations). No new evidence was found for these reviews. In the absence of evidence, the GDG based the discussion on their knowledge and the best clinical practice at the time and drafted recommendations for these clinical questions. Notes of the discussion were made live on screen.
5. SBR presented the evidence for blood glucose monitoring (the list of Excluded Studies, the Evidence Tables, the GRADE profiles summarising the evidence and the Evidence Summary and Recommendations). During the presentations the group had an opportunity

to discuss the evidence presented and ask questions. Notes of this discussion were made live on screen. The GDG drafted recommendations and research recommendations based on the evidence presented at this meeting.

6. SBR presented the review on HbA1c monitoring (the list of Excluded Studies, and the Evidence Summary and Recommendations). No new evidence was found for this review. In the absence of evidence, the GDG based the discussion on their knowledge and the best clinical practice at the time and drafted recommendations for this clinical question. Notes of the discussion were made live on screen.
7. DJ presented the outcomes from the survey of the GDG members regarding GDM interventions and clinically significant differences. During the presentations the group had an opportunity to ask questions.
8. PJ gave an overview of the proposed modelling approach to assess the cost-effectiveness of IADPSG/WHO 1999 diagnostic thresholds for gestational diabetes. During the presentation the group had an opportunity to ask questions.
9. RB informed the GDG that he will not be present at the January meeting and the meeting will be chaired by DJ. However, he would be participating in the pre-GDG meeting and his comments will be reported at the full GDG in January.

**Date, time and venue of the next meeting**

Tuesday 21<sup>st</sup> January 2014, 10:00 – 16:30 at the Royal College of Obstetricians and Gynaecologists, London